文献速递淋巴瘤

BET抑制剂GS-5829靶向慢性淋巴细胞白血病细胞及其支持性微环境

The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
PubMed 文献 · Leukemia · 2019-12-20

本研究报道新型BET抑制剂GS-5829在慢性淋巴细胞白血病(CLL)中的临床前活性。GS-5829通过 deregulation 关键信号通路抑制CLL细胞增殖并诱导凋亡,与BCR信号抑制剂联用具协同效应,并在模拟淋巴结微环境的共培养中抑制nurselike细胞信号及生长,为BET抑制剂在CLL中的临床评估提供依据。

要点

  • GS-5829抑制CLL细胞增殖并诱导凋亡,涉及BLK、AKT、ERK1/2、MYC及NF-κB通路。
  • GS-5829与ibrutinib、idelalisib或entospletinib联用具有协同抗白血病活性。
  • GS-5829可靶向CLL支持性微环境中的nurselike细胞信号与生长。

核心结论

  • GS-5829在临床前模型中显示抗CLL活性并可靶向支持性微环境,支持BET抑制剂在CLL中的临床评估。

研究设计与样本

  • 临床前研究,评估新型BET抑制剂GS-5829在CLL细胞及模拟淋巴结微环境共培养中的活性。

主要发现

  • GS-5829抑制CLL细胞增殖并诱导凋亡,伴随BLK、AKT、ERK1/2和MYC等信号通路失调。
  • IκBα调节提示GS-5829亦抑制NF-κB信号。
  • GS-5829诱导的凋亡源于内源性凋亡通路正调节因子BIM与负调节因子BCL-XL之间的失衡。
  • GS-5829与BTK抑制剂ibrutinib、PI3Kδ抑制剂idelalisib及SYK抑制剂entospletinib联用时抗白血病活性协同增强。
  • 在模拟淋巴结微环境的共培养中,GS-5829抑制nurselike细胞内的信号通路及其生长。

临床怎么用

  • GS-5829单药或与BCR信号抑制剂联用可能为CLL治疗提供新策略,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite major improvements in treatment outcome with novel targeted therapies, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, chronic lymphocytic leukemia (CLL) remains incurable in the majority of patients. Activation of PI3K, NF-κB, and/or MYC has been linked to residual disease and/or resistance in ibrutinib-treated patients. These pathways can be targeted by inhibitors of bromodomain and extra-terminal (BET) proteins. Here we report about the preclinical activity of GS-5829, a novel BET inhibitor, in CLL. GS-5829 inhibited CLL cell proliferation and induced leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC. IκBα modulation indicates that GS-5829 also inhibited NF-κB signaling. GS-5829-induced apoptosis resulted from an imbalance between positive (BIM) and negative regulators (BCL-XL) of the intrinsic apoptosis pathway. The antileukemia activity of GS-5829 increased synergistically in combinations with B-cell receptor signaling inhibitors, the BTK inhibitor ibrutinib, the PI3Kδ inhibitor idelalisib, and the SYK inhibitor entospletinib. In cocultures that mimic the lymph node microenvironment, GS-5829 inhibited signaling pathways within nurselike cells and their growth, indicating that BET inhibitors also can target the supportive CLL microenvironment. Collectively, these data provide a rationale for the clinical evaluation of BET inhibitors in CLL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kim E, Ten Hacken E, Sivina M, et al. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2019. PMID: 31862959. doi:10.1038/s41375-019-0682-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。